Microsoft and Bristol Myers Squibb have partnered to improve early detection of lung cancer using AI-powered radiology tools.
Key Details
- 1The collaboration aims to leverage Microsoft's scalable AI imaging platform and BMS’s oncology expertise.
- 2Focus is on optimizing early detection and care pathways for non-small cell lung cancer patients.
- 3Targeted initiatives include addressing low adherence to follow-up and improving workflows for underserved populations.
- 4Lung cancer claims about 125,000 U.S. lives annually, but early diagnosis via low-dose CT reduces mortality risk.
- 5The partnership seeks to deliver scalable diagnostic tools and efficiency gains for healthcare organizations.
Why It Matters
Early lung cancer detection has a clear impact on patient survival, but screening adherence remains low. Integrating scalable AI radiology platforms with oncology expertise could significantly improve workflows, diagnosis, and patient outcomes, especially for underserved populations.
Source
Radiology Business
Related News
•AuntMinnie
AI-Based Slab Reconstruction Streamlines Digital Breast Tomosynthesis
AI-driven slab reconstruction in DBT improves workflow efficiency without compromising diagnostic accuracy in breast cancer screening.
•AuntMinnie
AI Model Predicts Dosimetry for Lu-177 PSMA Therapy Using PET/CT
A machine learning PET/CT model shows promise for predicting radiation dose prior to Lu-177 PSMA therapy in prostate cancer patients.
•Radiology Business
DeepHealth's Prostate AI Gains FDA Clearance for MRI Workflows
DeepHealth, a RadNet subsidiary, received FDA clearance for its AI solution to assist prostate cancer detection and MRI workflow.